Heparin Treatment in Antiphospholipid Syndrome With Recurrent Pregnancy Loss: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the effect of combined heparin and aspirin compared with aspirin monotherapy in pregnant women with antiphospholipid syndrome and recurrent pregnancy loss. DATA SOURCES: We searched the PubMed database up to December 2009 for English-language studies using the key words "aspirin AND (heparin OR low molecular weight heparin), (antiphospholipid OR anticardiolipin OR aPL) AND pregnancy." METHODS OF STUDY SELECTION: Two hundred ninety- two studies were initially screened. Randomized controlled trials comparing the effect of heparin (unfractionated heparin or low molecular weight heparin) plus aspirin compared with aspirin alone on the live-birth rate in women with a history of at least two miscarriages and antiphospholipid antibodies were eligible. TABULATION, INTEGRATION, AND RESULTS: The pooled effect of unfractionated heparin and low molecular weight heparin was evaluable in three and two randomized controlled studies, respectively, with regard to live births, which was the major outcome. Overall, treatment effects were in favor of heparin against first-trimester losses (odd ratio [OR] 0.39, 95% confidence interval [CI] 0.24-0.65, number needed to treat 6). More specifically, unfractionated heparin displayed a significant effect (OR 0.26, 95% CI 0.14-0.48, number needed to treat 4), while the pooled effect of low molecular weight heparin was insignificant (OR 0.70, 95% CI 0.34-1.45). Combination therapy of either unfractionated heparin or low molecular weight heparin with aspirin failed to display any significant effect in the prevention of late-pregnancy losses. No significant differences were observed between treatment and control groups for any other outcomes. CONCLUSION: The combination of unfractionated heparin and aspirin confers a significant benefit in live births. However, the efficacy of low molecular weight heparin plus aspirin remains unproven, highlighting the urgent need for large controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two further meta-analyses showed similar reduction in recurrent miscarriage for the aspirin and UFH group (OR 0.26, 95% CI 0.14-0.48).164”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [164]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Weitz, J. I. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371007 · Cited by 1,533
Rai, R., Cohen, H., Dave, M., & Regan, L. (1997) · BMJ · doi:10.1136/bmj.314.7076.253 · Cited by 1,113
D'Cruz, D. P., Khamashta, M. A., & Hughes, G. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60279-7 · Cited by 992
Kutteh, W. H. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70610-5 · Cited by 803
Greer, I. A., & Nelson-Piercy, C. (2005) · Blood · doi:10.1182/blood-2005-02-0626 · Cited by 797
Estimation of a Common Effect Parameter from Sparse Follow-Up Data
Greenland, S., & Robins, J. M. (1985) · Biometrics · doi:10.2307/2530643 · Cited by 794
Cited by
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
(2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.06.048 · Cited by 1,308
“The combination of twice daily unfractionated heparin and low-dose aspirin appears to confer a significant benefit in pregnancies with aPLs and otherwise unexplained recurrent pregnancy loss; comparable efficacy of low molecular weight heparin has not been established (38, 39).”
BackgroundESHRE guideline: recurrent pregnancy loss
The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Nelen, W., Peramo, B., Quenby, S., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy004 · Cited by 1,002
“…low dose aspirin (75 – 100 mg/day), starting before conception, and a prophylactic dose heparin (unfractionated heparin [UFH] or low molecular weight heparin [LMWH]) starting at date of a positive pregnancy test, over no treatment (Empson et al. , 2005; Mak et al. , 2010; Ziakas et al. , 2010).”
Andreoli, L., Bertsias, G. K., Agmon-Levin, N., Brown, S., Cervera, R., Costedoat-Chalumeau, N., Doria, A., Fischer-Betz, R., Forger, F., Moraes-Fontes, M. F., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209770 · Cited by 945
Melamed, N., Baschat, A., Yinon, Y., Athanasiadis, A., Mecacci, F., Figueras, F., Berghella, V., Nazareth, A., Tahlak, M., McIntyre, H. D., et al. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13522 · Cited by 570
Dechartres, A., Boutron, I., Trinquart, L., Charles, P., & Ravaud, P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-1-201107050-00006 · Cited by 307
Diagnosis and management of the antiphospholipid syndrome
Chaturvedi, S., & McCrae, K. R. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.07.006 · Cited by 187
de Jesus, G. R., Agmon-Levin, N., Andrade, C. A., Andreoli, L., Chighizola, C. B., Flint Porter, T., Salmon, J., Silver, R. M., Tincani, A., & Ware Branch, D. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.02.003 · Cited by 187
“16) [80].”
BackgroundInfluentialRecurrent MiscarriageGreen‐top Guideline No. 17
Regan, L., Rai, R., Saravelos, S., Li, T., & the Royal College of Obstetricians and Gynaecologists (2023) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17515 · Cited by 158
Evidence-based management of recurrent miscarriages
Jeve, Y. B., & Davies, W. (2014) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.142475 · Cited by 165
“Therefore, it is recommended treatment for recurrent miscarriages with antiphospholipid syndrome[109,110] (Evidence level I).”
BackgroundShahine, L. K., & Lathi, R. B. (2015) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2014.10.002 · Cited by 148
Toth, B., Würfel, W., Bohlmann, M., Zschocke, J., Rudnik-Schöneborn, S., Nawroth, F., Schleußner, E., Rogenhofer, N., Wischmann, T., von Wolff, M., et al. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0586-4568 · Cited by 119
Current treatment of antiphospholipid syndrome: lights and shadows
Espinosa, G., & Cervera, R. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.88 · Cited by 112
Modern management of recurrent miscarriage
Homer, H. A. (2018) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12920 · Cited by 102
Contribution of immunology to implantation failure of euploid embryos
Franasiak, J. M., & Scott, R. T. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.04.019 · Cited by 93
Le rôle du stress oxydant dans les pathologies placentaires de la grossesse
Jauniaux, E. R. M., & Burton, G. J. (2016) · Journal de gynécologie, obstétrique et biologie de la reproduction. Supplément/Journal de gynécologie obstétrique et biologie de la reproduction · doi:10.1016/j.jgyn.2016.02.012 · Cited by 105
Overview on Biocompatibilities of Implantable Biomaterials
Wang, X. (2013) · InTech eBooks · doi:10.5772/53461 · Cited by 95
Recurrent miscarriage and thrombophilia: an update
McNamee, K. M., Dawood, F., & Farquharson, R. G. (2012) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32835585dc · Cited by 98
Pregnancy and autoimmune connective tissue diseases
Marder, W., Littlejohn, E., & Somers, E. C. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.05.002 · Cited by 84
Antiphospohlipid syndrome in obstetrics
Danza, Ã., Ruiz‐Irastorza, G., & Khamashta, M. A. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.006 · Cited by 85
High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome
Simchen, M. J., Dulitzki, M., Rofe, G., Shani, H., Langevitz, P., Schiff, E., & Pauzner, R. (2011) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2011.01236.x · Cited by 76
Does low-dose aspirin initiated before 11 weeks’ gestation reduce the rate of preeclampsia?
Chaemsaithong, P., Cuenca-Gómez, D., Plana, N., Gil, M. M., & Poon, L. C. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.08.047 · Cited by 79
Thrombophilia and early pregnancy loss
McNamee, K. M., Dawood, F., & Farquharson, R. G. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2011.10.002 · Cited by 76
de la Torre, Y. M., Pregnolato, F., D’Amelio, F., Grossi, C., Simone, N. D., Pasqualini, F., Nebuloni, M., Chen, P. P., Pierangeli, S. S., Bassani, N., et al. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.11.009 · Cited by 67
“Understanding the pathogenesis of aPL-associated miscarriages is pivotal to improve the pregnancy outcome, since there is a significant proportion of women unresponsive to the standard treatment with low dose aspirin and heparin [2,29,33,34].”
BackgroundThe treatment of anti-phospholipid syndrome: A comprehensive clinical approach
Chighizola, C. B., Andréoli, L., Gerosa, M., Tincani, A., Ruffatti, A., & Meroni, P. L. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.003 · Cited by 70
Khamashta, M. A., Taraborelli, M., Sciascia, S., & Tincani, A. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.002 · Cited by 81
Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder
D’Ippolito, S., Meroni, P. L., Koike, T., Veglia, M., Scambia, G., & Simone, N. D. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.05.004 · Cited by 70
Antithrombotic therapy for pregnancy loss
de Jong, P. G., Goddijn, M., & Middeldorp, S. (2013) · Human Reproduction Update · doi:10.1093/humupd/dmt019 · Cited by 70
“65), with little statistical heterogeneity (I(2) 10%; Ziakas et al., 2010).”
BackgroundInfluentialBradley, L. A., Palomaki, G. E., Bienstock, J., Varga, E., & Scott, J. A. (2012) · Genetics in Medicine · doi:10.1038/gim.0b013e31822e575b · Cited by 59
Classic and Cutting-Edge Strategies for the Management of Early Pregnancy Loss
Brezina, P. R., & Kutteh, W. H. (2013) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2013.10.011 · Cited by 66
Simone, N. D., D’Ippolito, S., Marana, R., Nicuolo, F. D., Castellani, R., Pierangeli, S. S., Chen, P. P., Tersigni, C., Scambia, G., & Meroni, P. L. (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12130 · Cited by 59
Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome
Arachchillage, D. J., Laffan, M., & Pericleous, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021331 · Cited by 62
“This treatment regime is based on several clinical studies and meta-analyses on the use of heparin and LDA in obstetric APS [45].”
MethodLMWH to prevent placenta‐mediated pregnancy complications: an update
Duffett, L., & Rodger, M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13209 · Cited by 55
“The second metaanalysis (Ziakas et al, 2010) included the five randomized controlled trials described above, using aspirin as a comparator, and reported an overall treatment effect in favour of heparin over aspirin for reduction in first trimester pregnancy loss (OR 0 39, 95% CI 0 24–0 65).”
BackgroundMethodResultInfluentialManagement of Women with Recurrent Pregnancy Losses and Antiphospholipid Antibody Syndrome
Kwak-Kim, J. Y.-H., Jesus, M. S. L. A., Alentajan-Aleta, L. T., Liao, A., Ota, K., Dambaeva, S. V., Beaman, K. D., Kim, J. W., & Gilman‐Sachs, A. (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12114 · Cited by 61
Cardiovascular Management in Pregnancy: Antithrombotic Agents and Antiplatelet Agents
Yarrington, C., Valente, A. M., & Economy, K. E. (2015) · Circulation · doi:10.1161/circulationaha.114.003902 · Cited by 62
“tion and increased the live birth rate in comparison with aspirin alone.(112,113) Although the data on LMWH with or without”
Everything the clinician needs to know about evidence-based anticoagulation in pregnancy
Scheres, L. J. J., Bistervels, I. M., & Middeldorp, S. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.08.001 · Cited by 55
Kutteh, W. H., Stanic, A. K., & Schust, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00013-5 · Cited by 47
Rheumatic diseases and pregnancy
Märker‐Hermann, E., & Fischer‐Betz, R. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283404d67 · Cited by 47
Lu, C. F., Liu, Y., & Jiang, H. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1404979 · Cited by 46
The challenge of pregnancy for patients with SLE
Ateka–Barrutia, O., & Khamashta, M. A. (2013) · Lupus · doi:10.1177/0961203313504637 · Cited by 49
Gerde, M., Ibarra, E. E. M., Kenzie, R. M., Suarez, C. F., Heer, C., Álvarez, R., Iglesias, M., Balparda, J., Beruti, E., & Rubinstein, F. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.08.004 · Cited by 45
Pregnancy in autoimmune rheumatic diseases: The importance of counselling for old and new challenges
Andréoli, L., Bazzani, C., Taraborelli, M., Reggia, R., Lojacono, A., Brucato, A. L., Meroni, P. L., & Tincani, A. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.08.004 · Cited by 42
“This condition is a main challengewhen it comes topregnancy failuredespite conventional treatment with low dose aspirin and lowmolecular weight heparin [7].”
BackgroundChallenges of Anticoagulation Therapy in Pregnancy
Fogerty, A. E. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0575-x · Cited by 43
Antiphospholipid Antibody Syndrome
Kutteh, W. H., & Hinote, C. D. (2014) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2013.10.004 · Cited by 50
Antiphospholipid antibody syndrome and reproduction
Kutteh, W. H. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000086 · Cited by 42
Intensity and Duration of Anticoagulation Therapy in Antiphospholipid Syndrome
Les, Í., Ruiz‐Irastorza, G., & Khamashta, M. A. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1304720 · Cited by 41
Investigation and Management of Recurrent Pregnancy Loss: A Comprehensive Review of Guidelines
Giouleka, S., Tsakiridis, I. G., Arsenaki, E., Kalogiannidis, I. A., Mamopoulos, A. M., Papanikolaou, E. G. E., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001133 · Cited by 41
Inherited and Acquired Thrombophilias
Rambaldi, M. P., Mecacci, F., Guaschino, S., & Paidas, M. J. (2013) · Reproductive Sciences · doi:10.1177/1933719113497282 · Cited by 38
Treatment of antiphospholipid syndrome beyond anticoagulation
Dobrowolski, C., & Erkan, D. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.001 · Cited by 36
Recurrent Early Pregnancy Loss
Stephenson, M. D. (2011) · Seminars in Reproductive Medicine · doi:10.1055/s-0031-1293199 · Cited by 36
Management of Systemic Lupus Erythematosus During Pregnancy
Sammaritano, L. R. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102658 · Cited by 41
Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome
Wijetilleka, S., Scoble, T., & Khamashta, M. A. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328354ae8c · Cited by 34
“No improvement of outcome however, was found when aspirin was combined with heparin in the analysis of late pregnancy loss prevention [60,61].”
BackgroundHoppe, B., Burmester, G. R., & Dörner, T. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328344c3f7 · Cited by 35
Gao, R., Zeng, R., Qing, P., Cheng, M., Cheng, K., Zhang, S., Chen, H., Jin, X., Qin, L., & Li, T. (2021) · American Journal of Reproductive Immunology · doi:10.1111/aji.13470 · Cited by 31
Ideguchi, H., Ohno, S., Uehara, T., & Ishigatsubo, Y. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8269-8 · Cited by 31
“The condition of APS is a main challenge when it comes to pregnancy failure despite conventional treatment with low-dose aspirin and low-molecular weight heparin [36].”
BackgroundElmahashi, M. O., Elbareg, A. M., Essadi, F., Ashur, B. M., & Adam, I. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-23 · Cited by 34
“However, a previous study showed that combination therapy with LMWH and aspirin failed to prevent late-pregnancy losses [24].”
ResultRecurrent miscarriage and autoimmunity
Bansal, A. S., Bajardeen, B., Shehata, H. A., & Thum, M. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.84 · Cited by 31
Liu, X., Qiu, Y., Yu, E. D., Xiang, S., Meng, R., Niu, K. F., & Zhu, H. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13219 · Cited by 29
High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant
Gebhart, J., Posch, F., Koder, S., Quehenberger, P., Perkmann, T., Kuessel, L., Ay, C., & Pabinger, I. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026948 · Cited by 29
Pregnancy and reproductive aspects of systemic lupus erythematosus
Andréoli, L., Crisafulli, F., & Tincani, A. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000415 · Cited by 29
Update on Antiphospholipid Syndrome: Ten Topics in 2017
Cavazzana, I., Andréoli, L., Limper, M. A., Franceschini, F., & Tincani, A. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0718-4 · Cited by 29
The role of anti-phospholipid antibodies in autoimmune reproductive failure
Pantham, P., Abrahams, V. M., & Chamley, L. (2016) · Reproduction · doi:10.1530/rep-15-0545 · Cited by 30
“concluded that heparin plus LDA is not more effective than LDA alone in treating women with APS-related fetal deaths but at least one of the trials included in that meta-analysis included a mixed population of patients only some of whom had APS (Ziakas et al. 2010).”
ResultZhang, T., Ye, X., Zhu, T., XIAO, X., Liu, Y., Wei, X., Liu, Y., Wu, C., Guan, R., Li, X., et al. (2015) · Medicine · doi:10.1097/md.0000000000001732 · Cited by 28
Yang, Z., Shen, X., Zhou, C., Wang, M., Liu, Y., & Zhou, L. (2020) · Lupus · doi:10.1177/0961203320967097 · Cited by 27
“With respect to aPLs tests, efforts to standardize have been made in past decades, but inconsistencies, inter-assay, and inter-laboratory variation remain, and problems with the interpretation and clinical cut-off values of these tests still exist.(28) Moreover, recent studies have suggested that patients can be risk-…”
ResultPaternal HLA ‐C is a risk factor in unexplained recurrent miscarriage
Meuleman, T., Haasnoot, G. W., Lith, J. M. M. V., Verduijn, W., Bloemenkamp, K. W. M., & Claas, F. H. J. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12797 · Cited by 31
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Carmona, L., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.003 · Cited by 34
Odiari, E. A., Mulla, M. J., Sfakianaki, A. K., Paidas, M. J., Stanwood, N. L., Gariepy, A. M., Brosens, J. J., Chamley, L., & Abrahams, V. M. (2012) · Human Reproduction · doi:10.1093/humrep/des288 · Cited by 27
Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome
Chighizola, C. B., Gerosa, M., Trespìdi, L., Giacomo, A. D., Rossi, F., Acaia, B., & Meroni, P. L. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.968129 · Cited by 30
“evaluated five randomized controlled trials, reporting a treatment effect in favor of UFH but not LMWH [46,20].”
BackgroundMastrolia, S. A., Mazor, M., Holcberg, G., Leron, E., Beharier, O., Loverro, G., & Erez, O. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0848 · Cited by 28
“65) with little statistical heterogeneity (I2 10 %) (60).”
BackgroundTóth, B., Bohlmann, M. K., Hancke, K., Kuon, R., Nawroth, F., von Otte, S., Rogenhofer, N., Rudnik‐Schöneborn, S., Schleußner, E., Tempfer, C., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1895-9940 · Cited by 26
Acquired and Inherited Thrombophilia Disorders in Pregnancy
Pierangeli, S. S., Leader, B., Barilaro, G., Willis, R., & Branch, D. W. (2011) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2011.02.016 · Cited by 26
Ying, Y., Zhong, Y., Zhou, C., Xu, Y., Wang, Q., Li, J., Wu, H., & Shen, X. (2012) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2012.04.002 · Cited by 23
Wen, S., Chang, W., Shen, H., & Wu, H.-C. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03032-0 · Cited by 23
Manning, R., Iyer, J., Bulmer, J. N., Maheshwari, A., & Choudhary, M. K. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1803241 · Cited by 26
“It is crucial to note that these recommendations are based on low quality evidence (Empson et al. 2005; Mak et al. 2010; Ziakas et al. 2010).”
BackgroundGuerby, P., Fillion, A., O'Connor, S. E., & Bujold, E. (2020) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2020.101974 · Cited by 25
Management of pregnant women with antiphospholipid antibodies
Ruffatti, A., Favarò, M., Calligaro, A., Zambon, A., & Ross, T. D. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1565995 · Cited by 25
Impact of Anticardiolipin Antibody on the Outcome of In Vitro Fertilization and Embryo Transfer
Zhong, Y., Ying, Y., Wu, H., Zhou, C., Xu, Y., Wang, Q., Li, J., Sheng, X.-T., & Li, J. (2011) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2011.01058.x · Cited by 21
Kutteh, W. H., Stovall, D. W., & Schust, D. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2758-2.00014-7 · Cited by 21
Hughes syndrome (the antiphospholipid syndrome): a disease of our time
Hughes, G. R. V. (2010) · Inflammopharmacology · doi:10.1007/s10787-010-0071-3 · Cited by 19
Obstetric antiphospholipid syndrome
Soto-Peleteiro, A., González-Echávarri, C., & Ruiz‐Irastorza, G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.05.001 · Cited by 16
Pregnancy in Rheumatic Disease Patients
Sammaritano, L. R. (2013) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31829ce35f · Cited by 15
“There is ongoing controversy about this standard treatment, however: certain meta-analyses suggest it is more useful for early losses than for late losses, and there is controversy about whether unfractionated heparin and lowmolecular-weight heparin are really equal in terms of their efficacy.(15) Another meta-analysi…”
ResultAnticoagulation in pregnancy complications
Middeldorp, S. (2014) · Hematology · doi:10.1182/asheducation-2014.1.393 · Cited by 20
Shi, T., Gu, Z.-D., & Diao, Q. (2021) · Medicine · doi:10.1097/md.0000000000026264 · Cited by 17
“In recent years, a number of clinical trials have shown that the combination of lowdose aspirin and LMWH is superior to aspirin alone in preventing pregnancy loss, and that there is no difference in the live birth rate among women on aspirin, aspirin combined with LMWH, and placebo.([32,33]) Xuefenglu et al([34]) foun…”
BackgroundIncidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome
Brock, C. O., Brohl, A. S., & Običan, S. G. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21107 · Cited by 14
Kitaori, T., Sugiura‐Ogasawara, M., Oku, K., Papisch, W., Ebara, T., Ozaki, Y., Katano, K., & Atsumi, T. (2015) · Lupus · doi:10.1177/0961203315595128 · Cited by 14
Pandey, M. S., Miller, C. M., Harris, E. N., & Weigel, P. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154124 · Cited by 13
“Hep has also been clinically used to prevent recurrent early pregnancy loss due to antiphospholipid syndrome, a complication associated with blood clotting in pregnant mothers that leads to miscarriage [5].”
Cáliz, R., Fontecha, P. D. D. C., Galindo-Izquierdo, M., Longo, F. J. L., Zamora, M. Á. M., Santamaría, A., Pliego, O. A., Lozano, M. J. C., Beltrán, M. P. D., Ortells, L. C., et al. (2019) · Reumatología Clínica · doi:10.1016/j.reuma.2018.11.004 · Cited by 13
Behcet's disease and pregnancy—a case report and literature review
Xu, C., & Bao, S. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12530 · Cited by 13
Miscarriage Definitions, Causes and Management: Review of Literature
(2017) · ARC Journal of Gynecology and Obstetrics · doi:10.20431/2456-0561.0203005 · Cited by 34
Meroni, P. L., Chighizola, C. B., Gerosa, M., Trespìdi, L., & Acaia, B. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.141407 · Cited by 12
Kaneko, K., Tsutsumi, S., Fujita, D., Sugiura‐Ogasawara, M., Mitsuda, N., Matsubara, K., Atsumi, T., Inoue, E., Takimoto, T., & Murashima, A. (2023) · Modern Rheumatology · doi:10.1093/mr/road062 · Cited by 12
Management of pregnancy and lactation
Sammaritano, L. R., & Bermas, B. L. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.03.007 · Cited by 11
Anti‐β2 glycoprotein I antibodies and pregnancy outcome in antiphospholipid syndrome
Liu, X. L., Xiao, J., & Zhu, F. (2012) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.12038 · Cited by 11
Current status and future prospects for the treatment of antiphospholipid syndrome
Marzooqi, A. A., Leone, A., Saleh, J. A., & Khamashta, M. A. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1178573 · Cited by 10
Suga, N., Sugimura, M., Koshiishi, T., Yorifuji, T., Makino, S., & Takeda, S. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.111.093690 · Cited by 10
“The signaling mechanism we present here may explain, in part, the beneficial effects of heparin on successful pregnancy outcomes in addition to the antithrombotic effect on the hypercoagulable state of the intervillous space [10].”
BackgroundDanaparoid is effective and safe for patients with obstetric antiphospholipid syndrome
Yoshihara, H., Sugiura‐Ogasawara, M., Kitaori, T., Katano, K., & Ozaki, Y. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1602241 · Cited by 10
“A meta-analysis revealed that LMWH (enoxaparin and dalteparin) did not improve the live birth rate [11].”
BackgroundNagata, M., Kaneko, K., Kohno, C., Mishima, S., Okazaki, Y., & Murashima, A. (2019) · Modern Rheumatology Case Reports · doi:10.1080/24725625.2019.1648633 · Cited by 10
“However, there have been cases of pregnancy failure despite conventional treatment [4].”
BackgroundDawood, F. (2013) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000164 · Cited by 10
“The review reported more favourable outcomes in the unfractionated heparin group [131].”
BackgroundProgress of the ALIFE2 study: A dynamic road towards more evidence
Hamulyák, E. N., de Jong, P. G., Scheres, L. J. J., Ewington, L. J., Middeldorp, S., Quenby, S. M., & Goddijn, M. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.03.015 · Cited by 9
“increase the chance of live birth in women with acquired thrombophilia, physicians are tempted to extrapolate this to women with inherited thrombophilia, and prescribe LMWH, ASA or both [10,11].”
BackgroundKaneko, K., Mishima, S., Goto, M., Mitsui, M., Tanigaki, S., Oku, K., Ozawa, N., Inoue, E., Atsumi, T., Sago, H., et al. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1386845 · Cited by 8
“However, the remaining cases have reported resulted in pregnancy failure despite conventional treatments [4,6].”
BackgroundMalhotra, P., Singh, C., Jain, A., & Tandon, R. (2023) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1858_21 · Cited by 10
Metadata
- Authors
- Ziakas, P. D., Pavlou, M., & Voulgarelis, M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Venue
- Obstetrics & Gynecology
- Published
- 2010-06
- Volume
- 115
- Issue
- 6
- Pages
- 1256-1262
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2083779542
- Cited by
- 185
- References
- 47
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 11 · 2022: 2 · 2021: 7 · 2020: 8 · 2019: 16 · 2018: 11 · 2017: 17 · 2016: 16 · 2015: 14 · 2014: 17 · 2013: 13 · 2012: 12
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- antiphospholipid syndrome, recurrent pregnancy loss, heparin, aspirin, low molecular weight heparin, unfractionated heparin, live birth rate, miscarriage prevention, combination anticoagulant therapy, pregnancy
- MeSH terms
- Abortion, Habitual, Aspirin, Drug Therapy, Combination, Female, Fibrinolytic Agents, Heparin, Humans, Pregnancy, Antiphospholipid Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.